Hematopoietic stem-cell transplantation in systemic sclerosis: an update

Area of Science:

• Immunology
• Hematology
• Rheumatology

Background:

• Systemic sclerosis (SSc) is a debilitating autoimmune disease characterized by fibrosis and vascular abnormalities.
• Autologous hematopoietic stem-cell transplantation (HSCT) has emerged as a potential therapeutic option for severe SSc.
• Recent research focuses on evaluating HSCT efficacy and safety compared to existing treatments.

Purpose of the Study:

• To review recent studies on autologous HSCT for systemic sclerosis.
• To assess the comparative effectiveness of HSCT against other treatments.
• To identify key considerations for HSCT in SSc management.

Main Methods:

• Review of recent publications on HSCT in SSc.
• Analysis of data from the randomized controlled American Scleroderma: Cyclophosphamide or Transplantation (SCOT) Trial.
• Inclusion of findings from uncontrolled prospective cohorts and retrospective analyses.

Main Results:

• The SCOT Trial demonstrated HSCT superiority over intravenous cyclophosphamide pulses in SSc patients.
• HSCT, including regimens with total body irradiation, was generally well tolerated.
• Improvements in skin involvement and lung volumes were observed post-HSCT in various cohorts.
• Transplant-related toxicity, mortality, and cardiac complications remain significant concerns.
• Translational studies suggest correlations between immune cell profiles and treatment response.

Conclusions:

• Increasing evidence supports HSCT benefit for rapidly progressive SSc.
• Optimal patient selection, pretransplantation workup, and posttransplant management require further establishment.